The EU generics industry has accused the US government of intervening in the ongoing discussion in the EU on the introduction of a Supplementary Protection Certificate (SPC) manufacturing waiver.
Marc-Alexander Mahl is President of Medicines for Europe. Europe’s healthcare model is under pressure. Populations are ageing in Europe – with the number of Europeans aged 65 or over set to rise by 45 million between 2015 and 2050.(1) This brings with it greater healthcare costs: currently, around 50 million EU citizens are estimated to […]
The European Commission launched on Thursday (12 October) a public consultation on supplementary protection certificates for pharmaceutical products and the so-called Bolar patent research exemption.
Any country that wants to inherit the European Medicines Agency (EMA) from London has to be easily accessible. Candidates will also need to increase their national agency’s resources, as staff are expected to move to the EMA, according to Adrian van den Hoven.
The harmonisation of different regulatory environments in the EU member states will help generic drugs enter the market, resulting in reduced prices for medicine and better patient access, Jacek Glinka told EURACTIV.com in an interview.